Bempikibart Clears Phase 2a Hurdle in Alopecia Areata, Setting Stage for Pivotal Program
QTTB has more than doubled off its 52-week low of $1.54 on elevated volume (4.4× avg).
Summary
Bempikibart achieved a 35.3% mean SALT reduction and 40% SALT-20 response in a Phase 2a alopecia areata trial, with a clean safety profile. Q32 Bio will advance to a registration-directed program, targeting a multi-billion dollar market.
Key Events · Product Development and Regulatory · QTTB
-
Phase 2a Primary Endpoint Met
At 36 weeks, bempikibart demonstrated a 35.3% mean reduction in SALT score (mITT) in patients with severe or very severe alopecia areata, with 40.0% achieving a SALT-20 response.
-
Clean Safety Profile
No Grade 3 or higher adverse events were observed; the most common events were mild injection site reactions (36.3%). Anti-drug antibodies were negligible, and no new safety signals emerged.
-
Registration-Directed Program Planned
Q32 will engage the FDA on a pivotal program for severe and very severe alopecia areata, with initiation targeted for 1H27. Studies in pediatric and moderate patient populations are also planned.
-
Large Market Opportunity
The US alopecia areata market is estimated to exceed $5B by 2037, with approximately 300,000 patients treated with advanced therapies. Bempikibart's non-JAK profile could capture significant share.
Analysis · QTTB · Life Sciences
In severe and very severe alopecia areata patients, bempikibart delivered a 35.3% mean SALT reduction and a 40% SALT-20 response rate, with no Grade 3+ adverse events. This marks the first biologic to demonstrate such efficacy in a disease where JAK inhibitors—despite their dominance—carry black box warnings. The clean safety profile and durable off-drug responses position bempikibart as a potential paradigm shift. Q32 now plans a registration-directed program with FDA engagement and initiation in 1H27, targeting a US market expected to exceed $5B by 2037. While the stock is trading near its 52-week high, reflecting elevated expectations, these data materially de-risk the asset and unlock a large commercial opportunity.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 40.7% of the 383 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTTB was trading at $19.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.5M. The 52-week trading range was $1.54 to $15.02. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.